Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Increases By 513.6%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 193,285 shares, an increase of 513.6% from the May 31st total of 31,498 shares. Approximately 4.6% of the shares of the stock are short sold. Based on an average daily volume of 12,405,724 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cyclacel Pharmaceuticals currently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Trading Up 2.0%

BGMS stock opened at $0.61 on Friday. Cyclacel Pharmaceuticals has a one year low of $0.57 and a one year high of $19.87. The firm has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.10. The firm has a market capitalization of $3.39 million, a PE ratio of -0.14 and a beta of -0.40.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last issued its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.